Bariatric surgery beats GLP-1s

Obesity treatment has a new head-to-head talking point — and it cuts against the hype cycle. At the American Society for Metabolic and Bariatric Surgery meeting in San Antonio on May 6, researchers from Yale, Vanderbilt, UT Health San Antonio, and Coreva-Scientific presented a pooled analysis of 30 studies covering more than 430,000 patients. The basic result was blunt: bariatric surgery outperformed GLP-1 drugs on every one-year outcome they measured. (asmbs.org) ### What actually got compared? This was not a single randomized trial. (asmbs.org) It was a systematic review and real-world analysis of studies that directly compared metabolic and bariatric surgery with GLP-1 receptor agonists, using PubMed and EMBASE searches and excluding studies that mixed the two treatments together. The main endpoint was weight loss at 12 months, with diabetes, hypertension, and high cholesterol remission as secondary outcomes. ### How big was the gap? Big enough that it is hard to wave away as noise. Surgery patients had 20.39 percentage points more total weight loss at 12 months than patients on GLP-1 drugs. Across seven studies, type 2 diabetes remission was 42.2% higher with surgery. Hypertension remission was 12.8 percentage points higher, and hyperlipidemia remission was 20.8 points higher. (asmbs.org) ### Why is that surprising? Because GLP-1s have looked almost unbeatable in ads, earnings calls, and cultural buzz. And to be fair, they are powerful drugs. In major obesity trials, semaglutide produced about 14.9% mean weight loss at 68 weeks, while tirzepatide reached 20.9% at the highest dose by 72 weeks. Those are real effects. But surgery is still playing a different game — especially for remission of obesity-linked disease, not just pounds lost. (asmbs.org) ### So does this mean surgery is “better”? Better at one-year effectiveness, yes. Better for every patient, no. Surgery is invasive. It brings operative risk, recovery time, lifelong nutrition monitoring, and the possibility of complications or revision procedures. GLP-1s are less invasive and easier to start, which is exactly why so many patients try them first. The tradeoff is durability — drug benefits often fade when treatment stops, while surgery tends to hold onto more of its effect over years. (drugs.com) ### Why does durability matter so much? Because obesity is not a short-term problem. If a treatment works only while you can afford it, tolerate it, and stay on it indefinitely, that changes the real-world math. The researchers leaned on that point directly — surgery’s edge is not just bigger early weight loss, but the fact that its benefits often persist after the procedure, while medication effects can shrink after discontinuation. (nejm.org) ### Is this the final word? Not really. The catch is that there still are no randomized controlled trials directly comparing modern GLP-1 drugs with bariatric surgery. This analysis helps fill the gap, but it is still stitching together different study designs, patient populations, and treatment settings. That makes the signal strong, but not perfectly clean. (asmbs.org) ### Why is this landing now? Because obesity care is being reorganized around GLP-1s in real time. These drugs changed expectations fast — among patients, doctors, and investors. But this review is a reminder that the older option did not get obsolete. It may still be the most effective tool for patients who need large, durable weight loss and a real shot at diabetes remission. (asmbs.org) ### Bottom line? The new result does not kill the GLP-1 boom. But it does puncture the idea that injections replaced surgery. Basically, GLP-1s widened the funnel into obesity treatment. Surgery still looks like the heavyweight option at the far end of that funnel — riskier, harder, but more powerful. (asmbs.org)